Drugs Controller General of India

Drugs Controller General of India
Agency name	Drugs Controller General of India
Jurisdiction	Republic of India
Headquarters	New Delhi
Chief1 position	Drugs Controller General
Parent agency	Central Drugs Standard Control Organization

Drugs Controller General of India

The Drugs Controller General of India is the national regulator for pharmaceuticals and medical devices in the Republic of India, operating under the Central Drugs Standard Control Organization and coordinating with the Ministry of Health and Family Welfare, the World Health Organization, the Food and Drug Administration, the European Medicines Agency. The office interfaces with the Indian Council of Medical Research, the National Institute of Virology, the Bureau of Indian Standards, the Reserve Bank of India and international partners such as the United States Department of Health and Human Services, the Medicines and Healthcare products Regulatory Agency, and the South Asian Association for Regional Cooperation.

History

The office evolved from colonial-era sanitary and drug licensing systems influenced by the Indian Medical Service, the Indian Council of Medical Research, the Public Health Act, and the Drugs and Cosmetics Act of 1940, drawing precedent from institutions like the Royal Pharmaceutical Society, the British Pharmacopoeia Commission, the Food and Drug Administration, and the European Directorate for the Quality of Medicines. Post-independence reforms under the Ministry of Health and Family Welfare, the National Pharmaceutical Pricing Authority, the Planning Commission, and the World Health Organization shaped its mandate alongside events such as the Swine Flu pandemic, the SARS outbreak, the HIV/AIDS crisis, and the COVID-19 pandemic. Legislative and institutional milestones involving the Parliament of India, the Supreme Court of India, the Central Drugs Standard Control Organization, the Drug Consultative Committee, and the National Pharmaceutical Pricing Policy further defined its role, with influence from international agreements like the Agreement on Trade-Related Aspects of Intellectual Property Rights, the World Trade Organization, and the International Council for Harmonisation.

Organization and Functions

The office sits within the Central Drugs Standard Control Organization and coordinates with the Ministry of Health and Family Welfare, the Directorate General of Health Services, the Indian Pharmacopoeia Commission, the National Institute of Biologicals, the National Accreditation Board for Testing and Calibration Laboratories, and state drug controllers across Delhi, Maharashtra, Tamil Nadu, Karnataka, and West Bengal. Functional units interact with the Drug Technical Advisory Board, the Drug Consultative Committee, the National Pharmaceutical Pricing Authority, the Bureau of Indian Standards, the Central Bureau of Investigation in matters of seizures, and the Narcotics Control Bureau for controlled substances. Regulatory interactions extend to the National Institute of Virology, the Indian Council of Medical Research, the Serum Institute of India, Bharat Biotech, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, Ranbaxy Laboratories, and the Central Forensic Science Laboratory for quality testing, inspections, licensing, clinical trial oversight, and pharmacovigilance coordination with the Pharmacovigilance Program of India.

Regulatory Framework and Responsibilities

Mandates derive from the Drugs and Cosmetics Act, the Drugs and Cosmetics Rules, Schedule M, Schedule Y, Schedule H, Schedule H1, and statutory guidance influenced by the World Health Organization, the International Council for Harmonisation, the United States Food and Drug Administration, the European Medicines Agency, the Medicines and Healthcare products Regulatory Agency, and the Pharmaceuticals and Medical Devices Agency (Japan). Responsibilities include approval of new drugs, clinical trial authorization, licensing of manufacturing facilities, inspection under the Central Drugs Standard Control Organization, import clearance with the Directorate General of Foreign Trade, pharmacovigilance with the Indian Pharmacopoeia Commission, adverse event reporting tied to the National Pharmacovigilance Programme, and enforcement actions that may involve the Central Bureau of Investigation, the Competition Commission of India, the Ministry of Commerce and Industry, and the Office of the Drug Controller General in interactions with multinational corporations such as GlaxoSmithKline, Pfizer, Novartis, Roche, and Johnson & Johnson.

Appointment and Tenure

The Drugs Controller is appointed through procedures involving the Ministry of Health and Family Welfare, recommendations from the Central Drugs Standard Control Organization, and oversight by the Appointments Committee of the Cabinet and the Cabinet Secretariat, with precedents set by high-level appointments in ministries such as the Ministry of Home Affairs and the Ministry of Finance. Tenure and removal processes have been shaped by case law from the Supreme Court of India, judgments from the High Courts of Delhi and Bombay, and administrative tribunals, while interactions with institutions like the Comptroller and Auditor General and the Lok Sabha Committee on Health and Family Welfare inform transparency and accountability.

Notable Initiatives and Policies

The office has overseen emergency use authorizations during public health emergencies such as the COVID-19 pandemic involving Serum Institute of India, Bharat Biotech, and Zydus Cadila; implementation of amended Schedule Y guidance for clinical trials; revisions to pharmacovigilance practices in collaboration with the Indian Pharmacopoeia Commission and the World Health Organization; regulatory alignment efforts with the International Council for Harmonisation and the European Medicines Agency; and initiatives targeting counterfeit medicines in coordination with the Central Bureau of Investigation, the Bureau of Indian Standards, INTERPOL, the World Health Organization, and the United Nations Office on Drugs and Crime. Partnerships with the National Institute of Biologicals, the National Accreditation Board for Testing and Calibration Laboratories, the Bureau of Indian Standards, the Indian Council of Medical Research, and the World Health Organization have supported capacity building, while policy dialogues have engaged stakeholders such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, Ranbaxy Laboratories, GlaxoSmithKline, Pfizer, Novartis, and Roche.

Criticisms and Controversies

Criticism has arisen over approval timelines, transparency disputes heard before the Supreme Court of India and the High Courts of Delhi and Bombay, allegations of regulatory capture involving multinational corporations like Ranbaxy Laboratories and GlaxoSmithKline, enforcement actions against manufacturers such as Cipla and Sun Pharmaceutical Industries, and debates on clinical trial ethics involving academic institutions like the Indian Council of Medical Research and hospitals such as All India Institute of Medical Sciences. Controversies include challenges related to counterfeit drug seizures coordinated with the Central Bureau of Investigation and INTERPOL, disputes over import-clearance decisions involving the Directorate General of Foreign Trade, and scrutiny by parliamentary panels including the Lok Sabha Committee on Health and Family Welfare and audit findings by the Comptroller and Auditor General.

Category:Pharmaceutical regulatory authorities Category:Medical and health organisations based in India